Evidence map›Paper›PMID 40522120›Full record

ArticleeLife2025

Targeted protein degradation by KLHDC2 ligands identified by high-throughput screening.

Han Zhou, Tonglian Zhou, Wenli Yu, Liping Liu, Yeonjin Ko, Kristen A Johnson, Ian A Wilson, Peter G Schultz, Michael J Bollong

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Han Zhou *Department of Chemistry, Scripps Research, La Jolla, United States.
Tonglian Zhou *Department of Chemistry, Scripps Research, La Jolla, United States.
Wenli YuDepartment of Integrative Structural and Computational Biology, Scripps Research, La Jolla, United States.
Liping LiuDepartment of Chemistry, Scripps Research, La Jolla, United States.
Yeonjin KoChemical & Biological Integrative Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Kristen A JohnsonDepartment of Biology, Calibr-Skaggs at Scripps Research, La Jolla, United States.
Ian A WilsonDepartment of Integrative Structural and Computational Biology, Scripps Research, La Jolla, United States.
Peter G SchultzDepartment of Chemistry, Scripps Research, La Jolla, United States.
Michael J BollongDepartment of Chemistry, Scripps Research, La Jolla, United States.ORCID https://orcid.org/0000-0001-9439-1476

Funding

Synthesis at the Interface of Chemistry and BiologyR35GM145323 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI PETER G SCHULTZ · 2022 to 2026
$3.4M
Methods and approaches to expand the pharmacological toolsetR35GM146865 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI Michael J Bollong · 2022 to 2026
$2.3M
NIGMS NIH HHS GM145323NIGMS NIH HHS GM146865NIGMS NIH HHS R35 GM145323NIGMS NIH HHS R35 GM146865
6 · The paper itself

Abstract

Proteolysis-targeting chimeras (PROTACs) enable the selective and sub-stoichiometric elimination of pathological proteins, yet only two E3 ligases are routinely used for this purpose. Here, we expand the repertoire of PROTAC-compatible E3 ligases by identifying a novel small molecule scaffold targeting the ubiquitin E3 ligase KLHDC2 using a fluorescence polarization-based high-throughput screen. We highlight the utility of this ligand with the synthesis of PROTACs capable of potently degrading BRD4 in cells. This work affords additional chemical matter for targeting KLHDC2 and suggests a practical approach for identifying novel E3 binders by high-throughput screening.

Indexed as

High-Throughput Screening AssaysProteolysisTranscription FactorsUbiquitin-Protein LigasesBromodomain Containing ProteinsCell Cycle ProteinsHumansLigandsNuclear ProteinsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsLigandsNuclear ProteinsTranscription FactorsUbiquitin-Protein Ligasesbiochemistrychemical biologyE3 ligasehigh-throughput screeninghumanKLHDC2PROTAC

Identifiers

PMID40522120
PMCPMC12169847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.